A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Balchem Corporation (“Balchem,” the “Company,” “we” or “us”), was incorporated in the State of Maryland in 1967. We develop, manufacture, distribute and market specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, plant nutrition, sterilization, fumigation, and industrial markets. Our three reportable segments are strategic businesses that offer products and services to different markets: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated". We sell our products through our own sales force, independent distributors and sales agents.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 1.0B | 1.0B | 954M | 922M | 942M | 799M |
| Net Income | 155M | 155M | 128M | 109M | 105M | 96M |
| EPS | $4.75 | $4.75 | $3.93 | $3.35 | $3.25 | $2.94 |
| Free Cash Flow | 217M | 217M | 182M | 184M | 89M | 124M |
| ROIC | 11.8% | 11.6% | 10.7% | 9.4% | 10.2% | 10.7% |
| Gross Margin | 35.7% | 35.7% | 35.3% | 32.7% | 29.8% | 30.4% |
| Debt/Equity | 0.16 | 0.16 | 0.20 | 0.33 | 0.52 | 0.15 |
| Dividends/Share | $0.87 | $0.96 | $0.87 | $0.79 | $0.71 | $0.57 |
| Operating Income | 209M | 209M | 183M | 159M | 145M | 128M |
| Operating Margin | 20.2% | 20.2% | 19.2% | 17.3% | 15.4% | 16.0% |
| ROE | 12.3% | 12.9% | 11.7% | 10.9% | 11.6% | 11.3% |
| Shares Outstanding | 33M | 33M | 33M | 32M | 32M | 33M |
BALCHEM CORP passes 5 of 9 quality checks, suggesting mixed fundamentals.
BALCHEM CORP trades at 37.2x trailing earnings, compared to its 15-year median P/E of 40.7x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 26.6x vs a median of 29.9x. The company's 5-year average ROIC is 10.5% with a gross margin of 32.8%. Total shareholder yield (dividends + buybacks) is 2.4%. At current prices, the estimated annualized return to fair value is +8.2%.
BALCHEM CORP (BCPC) has a current P/E ratio of 37.2, compared to its historical median P/E of 40.7. The stock is currently considered Fair based on its historical valuation range.
BALCHEM CORP (BCPC) has a 5-year average return on invested capital (ROIC) of 10.5%. This indicates solid capital allocation.
BALCHEM CORP (BCPC) has a market capitalization of $5.8B. It is classified as a mid-cap stock.
Yes, BALCHEM CORP (BCPC) pays a dividend with a trailing twelve-month yield of 0.49%. The company also returns capital through share buybacks, with a buyback yield of 1.87%.
Based on historical P/E analysis, BALCHEM CORP (BCPC) appears fair. The current P/E of 37.2 is 9% below its historical median of 40.7. The estimated fair value CAGR (P/E method) is 9.0%.
BALCHEM CORP (BCPC) operates in the Chemicals & Allied Products industry, within the Materials sector.
BALCHEM CORP (BCPC) reported annual revenue of $1.0 billion in its most recent fiscal year, based on SEC EDGAR filings.
BALCHEM CORP (BCPC) has a net profit margin of 14.9%. This is a healthy margin.
BALCHEM CORP (BCPC) generated $217 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
BALCHEM CORP (BCPC) has a debt-to-equity ratio of 0.16. This indicates a conservatively financed balance sheet.
BALCHEM CORP (BCPC) reported earnings per share (EPS) of $4.75 in its most recent fiscal year.
BALCHEM CORP (BCPC) has a return on equity (ROE) of 12.9%. This indicates moderate shareholder returns.
BALCHEM CORP (BCPC) has a 5-year average gross margin of 32.8%. This indicates decent pricing power.
The Ledger Terminal provides 16 years of financial data for BALCHEM CORP (BCPC), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
BALCHEM CORP (BCPC) has a book value per share of $38.57, based on its most recent annual SEC filing.
No recent press releases.